HomeAI · summaries
Storia in 3 fonti
What's Going On With Celcuity Stock On Tuesday? - Celcuity (NASDAQ:CELC)
Celcuity reported Phase 3 data showing gedatolisib improved progression-free survival in PIK3CA-mutated breast cancer.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
- ·
endpoints.news
Celcuity aims for broad FDA approval after positive breast cancer readout
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a third-quarter FDA submission.
